Pharmaceuticals
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022
* Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus * Thirteen key clinical milestones...
2023-03-31 18:30
4139
Boao Forum for Asia Enters the Healthcare Sector
Boao Lecheng International Medical Tourism Pilot Zone at Hainan Free Trade Port Helps China's Medical Sector Expand into Global Markets QIONGHAI, China, March 30, 2023 /PRNewswire/ -- Boao, the seaside resort and convention destination on the South China Sea coast, has again caught the attention...
2023-03-31 10:00
1402
Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China
SHANGHAI, March 31, 2023 /PRNewswire/ -- Ablaze Pharmaceuticals, a biotech company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients inChina, today announced the development plans of a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC...
2023-03-31 10:00
2419
Genscript Biotech Reports 2022 Annual Results*
Non-Cell Therapy Achieved 31.4% Adjusted Net Profit Growth Cell Therapy Business Revenue Surged By 70% * Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, representing an increase of 27.7% as compared with approximatelyUS$490.1 million for the year e...
2023-03-31 08:40
2681
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022
SHANGHAI, March 31, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced its financial results for the full year...
2023-03-31 07:30
3558
Kintor Pharma Announces 2022 Annual Results and Recent Business Progress
SUZHOU, China, March 30, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended31 Decembe...
2023-03-31 00:33
2906
Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference
A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical trials of patients with mild Alzheimer's Disease (AD) and the likely therapeutic benefit of oral Xanamem in this population SYDNEY, March 30, 2023 /PRNewswire/ -- Actinogen Medical ASX: ACW ("ACW" or "...
2023-03-30 21:00
1553
ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization
BASEL, Switzerland, March 30, 2023 /PRNewswire/ -- ACROBiosystems has begun to narrow its focus into helping accelerate the process between preclinical, clinical and commercialization. With over 10 years development, ACROBiosystems continues to surprise and bring new solutions to the pharmaceutic...
2023-03-30 20:51
1747
Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC
MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the interna...
2023-03-30 20:00
2891
ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization
NEWARK, Del., March 30, 2023 /PRNewswire/ -- With more than 10 years of experience in protein development, ACROBiosystems has continuously demonstrated its strength in developing products and services throughout the entire drug development process. As such, ACROBiosystems has begun to narrow its ...
2023-03-30 18:54
1726
DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200
SEOUL, South Korea, March 30, 2023 /PRNewswire/ -- DXVX announces that its affiliated company Oxford Vacmedix (OVM) has completed Phase 1a trial of cancer vaccine and plans to proceed Phase1b trial of OVM-200. DxVx Co., Ltd. is the Korean Stock market (KOSDAQ) listed company and is the largest s...
2023-03-30 17:39
1643
Great Place To Work unveils Best Workplaces in the Inaugural Singapore Healthcare and Biopharma List 2023
Employees express trust in leaders' competence and integrity and value fairness and impartiality as part of the workplace culture SINGAPORE, March 30, 2023 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture announced the 10 companies who are Best WorkplacesTM in its ...
2023-03-30 12:00
2210
ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China
SHENZHEN, China, March 29, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration ("NMPA") for Phase I clinical trial inChina on March 29, 2023. Previously, MVR-C5252 also obt...
2023-03-30 08:00
1546
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients
SHANGHAI, March 30, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that as ofMarch 29, 2023, the company has conducted 13 clinical studies cover...
2023-03-30 08:00
2227
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063
- ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn's disease - LOS ANGELES, March 30, 2023 /PRNewswire/ -- Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology ...
2023-03-30 03:32
2321
bitBiome and Kaken Pharmaceuticals sign joint research agreement on the discovery of drugs for infectious diseases
-The joint research will use bitBiome's drug discovery platform technology to search for drug candidate substances- TOKYO, March 29, 2023 /PRNewswire/ -- bitBiome, Inc. (Head office: Shinjuku-ku,Tokyo; President: Yuji Suzuki; hereafter 'bitBiome') and Kaken Pharmaceuticals (Head office: Bunkyo-k...
2023-03-29 22:00
1821
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth
* Su-jin Park joins HanAll Biopharma in a shared leadership role to strengthen pharmaceutical business in Korea, supporting growth in domestic drug sales * Sean Jeong, who has been serving as Co-CEO since March 2021, will continue to lead HanAll's R&D, including its subsidiary HanAll Pharmace...
2023-03-29 19:00
1290
BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia
BRATISLAVA, Slovakia, March 29, 2023 /PRNewswire/ -- BGI Genomics is pleased to announce the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya. Zentya is a Slovak-based company that is passionate about providing patients with the latest technology in genetic screenin...
2023-03-29 16:00
1176
Fosun Pharma Announces its 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public
SHANGHAI, March 29, 2023 /PRNewswire/ -- On March 27, 2023, the release date of its 2022 Annual Report, Fosun Pharma (stock code: 600196.SH; 02196.HK) also released the2022 Corporate Social Responsibility Report, its 15th CSR report since the first which was issued in 2009. As before, Fosun Pharm...
2023-03-29 14:06
1559
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer
SUZHOU, China, March 29, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that the U.S. Food an...
2023-03-29 14:00
2873
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 292 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 254 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 250 media titles]
2024-04-30 15:13Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2934
